Moderna Stock Jumps on Confirmed Nasdaq-100 Index Inclusion

Moderna Inc. (MRNA) shares rose in pre-market trading after Nasdaq announced the biotechnology company will be added to the closely followed Nasdaq-100 Index. The inclusion is expected to create significant structural demand from investment funds that track the benchmark.

Index Inclusion Details

Nasdaq confirmed after the market close on October 1 that Moderna will officially join the index effective October 9, replacing Warner Bros. Discovery. Inclusion in a major benchmark like the Nasdaq-100 is a significant event for a company's stock, as it forces buying from passive index funds and exchange-traded funds (ETFs).

According to the announcement's context, more than $800 billion in assets under management are linked to the index. This mechanical buying from tracker funds rebalancing their portfolios is a primary driver behind the stock's recent gains.

Recent Volatility and Analyst Views

The index news comes amid a period of high volatility and sharp gains for Moderna. The stock has surged approximately 222% since mid-August, a rally initially sparked by positive Phase 3 trial data for its personalized cancer vaccine developed in partnership with Merck.

Ad

However, this rapid appreciation recently drew a skeptical review from Wall Street. Citi analyst Geoff Meacham downgraded Moderna to Sell from Neutral, arguing that the stock's valuation had moved well beyond what its current drug pipeline could justify, despite raising his price target to $80.

Market Reaction

In pre-open trading, Moderna stock climbed 2.2% to $193.15, trading near its 52-week high of $208.90. The move was company-specific, as peers such as BioNTech and Pfizer saw comparatively muted activity.

Investors are also looking ahead to a key data presentation at the European Society for Medical Oncology (ESMO) on October 24. Operationally, Moderna recently appointed Juan Andres to the newly created role of Chief Operating Officer, signaling a focus on scaling its manufacturing capacity to support its oncology ambitions.